| 1. |
- Gustafsson, Peik, et al.
(författare)
-
Treatment of Attention Deficit/Hyperactivity Disorder With Amphetamine: Short-Term Effects on Family Interaction.
- 2008
-
Ingår i: Journal of Attention Disorders. - : SAGE Publications. - 1557-1246 .- 1087-0547. ; 12:1, s. 83-91
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: This research seeks to study the impact on family function after 3 months of treatment with amphetamine. Method: A total of 43 children, 6 to 11 years of age, with ADHD were treated with amphetamine for 3 months. Family function was studied before and after treatment by parent self-rating and independent observer ratings of videotaped parent—child interactions. Results: The families with a child with ADHD were found to be more dysfunctional than control families. Families with children with severe ADHD behavior showed evidence of more family dysfunction compared to families with children with less severe ADHD behavior. After 3 months of treatment with amphetamine, the children's behavior and the mother's well-being and some aspects of parent-reported and observer-rated family functioning improved. Conclusion: This study gives support to the notion that some aspects of family dysfunction may be related to the child's ADHD behavior.
|
|
| 2. |
- Johnson, Mats, 1956, et al.
(författare)
-
Open-label trial of atomoxetine hydrochloride in adults with ADHD.
- 2010
-
Ingår i: Journal of Attention Disorders. - : SAGE Publications. - 1087-0547 .- 1557-1246. ; 13:5, s. 539-545
-
Tidskriftsartikel (refereegranskat)abstract
- Background: While atomoxetine is an established treatment for attention-deficit/hyperactivity disorder in children, few studies have examined its efficacy for adults. Methods: Open-label trial of atomoxetine in 20 individuals with ADHD, aged 19-47 years, for 10 weeks, and a total of one year for responders. Results: Ten patients met primary efficacy criteria at 10 weeks. Only one patient completed the whole study. Six patients discontinued before 10 weeks and thirteen at 10 weeks or later, mainly because of side-effects (aggression, depressed mood, raised liver enzymes, thyroid hormones, diastolic blood pressure), decreasing efficacy or non-compliance. Conclusion: Fifty percent responded to treatment, but only one patient (5%) felt sufficient improvement to continue for one year. Dosage may have been too low, and baseline impairment too high, for atomoxetine to have sufficient effect on ADHD symptoms in our group of adults. The majority had few side-effects, but several terminated treatment because of adverse effects.
|
|
| 3. |
- Myren, Karl-Johan, et al.
(författare)
-
Atomoxetine's Effect on Societal Costs in Sweden
- 2010
-
Ingår i: Journal of Attention Disorders. - : SAGE Publications. - 1557-1246 .- 1087-0547. ; 13:6, s. 618-628
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: To compare societal costs between patients treated with atomoxetine and placebo in Sweden. Method: Ninety-nine pediatric ADHD patients were randomized to a 10-week double-blind treatment with atomoxetine (n = 49) or placebo (n = 50). All parents received four sessions of psycho-education. Parents filled out a resource utilization questionnaire covering the 10 weeks prior to treatment and the 10-week on-treatment period. Published unit costs/prices were used to calculate costs. Results: Mean on-treatment costs in the atomoxetine group (SEK [Swedish Krona] 4,558) were significantly lower compared with placebo (SEK 7,684) after adjusting for baseline costs and site (p = .007). All 99 patients entered an open atomoxetine extension phase. Both groups had numerical reductions in direct and indirect costs while on atomoxetine treatment during the extension phase. The atomoxetine medication costs were offset by the reductions in direct nonmedical and indirect costs. Conclusions: These data provide preliminary evidence that atomoxetine together with parental psycho education reduces nonmedication costs associated with ADHD in Sweden. (J. of Att. Dis. 2010; 13(6) 618-628)
|
|
| 4. |
- Rasmussen, Kirsten, et al.
(författare)
-
Differences in psychiatric problems and criminality between individuals treated with central stimulants before and after adulthood
- 2019
-
Ingår i: Journal of Attention Disorders. - : Sage Publications. - 1087-0547 .- 1557-1246. ; 23:2, s. 173-180
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: The evidence for central stimulant (CS) treatment in ADHD is strong in some respects but not with respect to unselected clinical material and long-term effects over the life course cycle. The objective of this study was to explore differences in vocational, psychiatric, and social impairment, including crime and substance abuse, among adults with ADHD, treated or not, with CS drugs before age 18. Method: A clinical population of men (N = 343) and women (N = 129) seeking CS treatment as adults was assessed within a specific program for such treatment. Clinical information and data collected by structured instruments were available. Results: Previously CS-treated persons had a lower frequency of problems (alcohol/substance abuse, criminality), and of certain psychiatric disorders (depressive, anxiety and personality ones). Most differences were substantial. Conclusion: The study supports the assumption that CS treatment during childhood/adolescence offers some protection against the development of a range of problems known to characterize adult ADHD patients.
|
|
| 5. |
- Rasmussen, Kirsten, et al.
(författare)
-
Untreated ADHD in Adults Are There Sex Differences in Symptoms, Comorbidity, and Impairment?
- 2009
-
Ingår i: Journal of Attention Disorders. - : SAGE Publications. - 1557-1246 .- 1087-0547. ; 12:4, s. 353-360
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: To analyze sex differences among adult, never-treated patients referred for central stimulant treatment of ADHD. Method: Data for 600 consecutive patients from northern Norway referred for evaluation by an expert team during 7 years were analyzed. General background information, diagnostic and social history, and symptom profiles were compared between previously never-treated men and women. Results: The sex ratio was skewed. Of the previously untreated patients, more than 20% fell outside society's ordinary vocational activities or social benefit system. Most patients had the combined form, one third the inattentive type, and only 2% the hyperactive/impulsive subtype. Abuse and criminality were more common among men, and affective, eating, and somatization disorders were more common among women. Otherwise few sex differences were found. Conclusion: AD/HD symptom intensity and subtypes did not differ between the sexes and was to age. Symptom intensity was linked with criminality, abuse, and other psychiatric problems, differentially for two sexes. (J. of Att. Dis. 2009; 12(4) 353-360)
|
|
